Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Liraglutide, a medication commonly used to treat diabetes, has shown promising results in reducing chronic migraine in ...

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a ...

GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...